There is no question that millions of Americans are in need of potentially life-saving medications to prevent strokes from occurring. In fact, as discussed in a recent Bio Pharma Dive article, strokes are up in the U.S.
The conventional treatment for strokes for decades was Warfarin (Coumadin), which is a blood thinning medication. In 2010, the U.S. Food and Drug Administration (FDA) approved the first of a new class of drugs to compete against Warfarin. This new class of drugs was labeled new or novel anticoagulants (NAOCs) and works in a different way that Warfarin. This new drug was called Xarelto, and when it came on the market, many patients started taking it instead of Warfarin. Continue reading